Patients under anti-platelet therapy.
Interruption or maintenance of anti-platelet agents (APAs) during surgical or invasive procedures is associated with an increase in cardiovascular or haemorrhagic complications, respectively. The pharmacology and indications of aspirin, clopidogrel and prasugrel are summarised. The utility and risks of interruption, the optimal delay between stent implantation and surgery, the appropriate window of preoperative interruption, the potential usefulness of bridging, the safest delay between the end of surgery and resumption of APA are detailed in this review. Some non-evidence-based suggestions are given to help the physicians in their daily clinical practice.
Albaladejo
Pierre
P
Department of Anaesthesiology and Intensive Care, Grenoble University Hospital, Grenoble CEDEX 9, France.
Samama
Charles Marc
CM
D000818:Animals; D001778:Blood Coagulation Disorders / Q000097:blood / Q000188:drug therapy*; D001792:Blood Platelets / Q000187:drug effects; D006801:Humans; D010974:Platelet Aggregation / Q000187:drug effects; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*
D010975:Platelet Aggregation Inhibitors